Your browser doesn't support javascript.
loading
Current directions in tau research: Highlights from Tau 2020.
Sexton, Claire; Snyder, Heather; Beher, Dirk; Boxer, Adam L; Brannelly, Pat; Brion, Jean-Pierre; Buée, Luc; Cacace, Angela M; Chételat, Gaël; Citron, Martin; DeVos, Sarah L; Diaz, Kristophe; Feldman, Howard H; Frost, Bess; Goate, Alison M; Gold, Michael; Hyman, Bradley; Johnson, Keith; Karch, Celeste M; Kerwin, Diana R; Koroshetz, Walter J; Litvan, Irene; Morris, Huw R; Mummery, Catherine J; Mutamba, James; Patterson, Marc C; Quiroz, Yakeel T; Rabinovici, Gil D; Rommel, Amy; Shulman, Melanie B; Toledo-Sherman, Leticia M; Weninger, Stacie; Wildsmith, Kristin R; Worley, Susan L; Carrillo, Maria C.
Afiliação
  • Sexton C; Alzheimer's Association, Chicago, Illinois, USA.
  • Snyder H; Alzheimer's Association, Chicago, Illinois, USA.
  • Beher D; Asceneuron, Lausanne, Switzerland.
  • Boxer AL; Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA.
  • Brannelly P; Alzheimer's Disease Data Initiative, Kirkland, WI, USA.
  • Brion JP; Laboratory of Histology, Neuroanatomy and Neuropathology, Faculty of Medicine, Université Libre de Bruxelles, Brussels, Belgium.
  • Buée L; Univ Lille, Inserm, CHU-Lille, Lille Neuroscience and Cognition, Place de Verdun, Lille, France.
  • Cacace AM; Neuroscience and Platform Biology, Arvinas, New Haven, USA.
  • Chételat G; Normandie Univ, UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging of Neurological Disorders", Institut Blood and Brain @ Caen-Normandie, Cyceron, Caen, France.
  • Citron M; Neuroscience TA, Braine l'Alleud, UCB Biopharma, Brussels, Belgium.
  • DeVos SL; Translational Sciences, Denali Therapeutics, San Francisco, California, USA.
  • Diaz K; Cure PSP, New York, New York, USA.
  • Feldman HH; Alzheimer's Disease Cooperative Study, Department of Neurosciences, University of California, San Diego, La Jolla, California, USA.
  • Frost B; Sam & Ann Barshop Institute for Longevity and Aging Studies, Glenn Biggs Institute for Alzheimer's & Neurodegenerative Disorders, Department of Cell Systems & Anatomy, University of Texas Health San Antonio, San Antonio, Texas, USA.
  • Goate AM; Ronald M. Loeb Center for Alzheimer's Disease, Department of Neuroscience, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Gold M; AbbVie, Neurosciences Development, North Chicago, Illinois, USA.
  • Hyman B; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Johnson K; Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Karch CM; Department of Psychiatry, Washington University in St. Louis, St. Louis, Missouri, USA.
  • Kerwin DR; Kerwin Medical Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Koroshetz WJ; National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, USA.
  • Litvan I; Parkinson and Other Movement Disorders Center, Department of Neurosciences, University of California San Diego, San Diego, California, USA.
  • Morris HR; Department of Clinical and Movement Neuroscience, UCL Queen Square Institute of Neurology, London, UK.
  • Mummery CJ; Dementia Research Centre, National Hospital for Neurology and Neurosurgery, University College London, London, UK.
  • Mutamba J; Longwood Fund, Boston, Massachusetts, USA.
  • Patterson MC; Departments of Neurology, Pediatrics and Medical Genetics, Mayo Clinic, Rochester, Minnesota, USA.
  • Quiroz YT; Departments of Neurology and Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Rabinovici GD; Memory & Aging Center, Departments of Neurology, Radiology & Biomedical Imaging, University of California San Francisco, San Francisco, California, USA.
  • Rommel A; Tau Consortium, Rainwater Charitable Foundation, Fort Worth, Texas, USA.
  • Shulman MB; Neurodegeneration Development Unit, Biogen, Boston, Massachusetts, USA.
  • Toledo-Sherman LM; Tau Consortium, Rainwater Charitable Foundation, Fort Worth, Texas, USA.
  • Weninger S; FBRI, Cambridge, Massachusetts, USA.
  • Wildsmith KR; Department of Biomarker Development, Genentech, South San Francisco, California, USA.
  • Worley SL; Independent science writer, Bryn Mawr, Pennsylvania, USA.
  • Carrillo MC; Alzheimer's Association, Chicago, Illinois, USA.
Alzheimers Dement ; 18(5): 988-1007, 2022 05.
Article em En | MEDLINE | ID: mdl-34581500
Studies supporting a strong association between tau deposition and neuronal loss, neurodegeneration, and cognitive decline have heightened the allure of tau and tau-related mechanisms as therapeutic targets. In February 2020, leading tau experts from around the world convened for the first-ever Tau2020 Global Conference in Washington, DC, co-organized and cosponsored by the Rainwater Charitable Foundation, the Alzheimer's Association, and CurePSP. Representing academia, industry, government, and the philanthropic sector, presenters and attendees discussed recent advances and current directions in tau research. The meeting provided a unique opportunity to move tau research forward by fostering global partnerships among academia, industry, and other stakeholders and by providing support for new drug discovery programs, groundbreaking research, and emerging tau researchers. The meeting also provided an opportunity for experts to present critical research-advancing tools and insights that are now rapidly accelerating the pace of tau research.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Alzheimer / Disfunção Cognitiva Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Alzheimer / Disfunção Cognitiva Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article